Synergistic interactions between ampakines and antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 392-397

  Johnson, Steven A ^a   Nguyen T, Luu ^a   Herbst, Todd A ^a   Knapp, Richard ^a   Lutz, David ^a   Arai, Amy ^a,b   Rogers, Gary A ^a   Lynch, Gary ^a,b  

^a Cortex Pharmaceut Incorporated ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; AMPAKINE DERIVATIVE; AMPHETAMINE DERIVATIVE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; METHAMPHETAMINE; NEUROLEPTIC AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CATALEPSY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; CENTRAL NERVOUS SYSTEM STIMULANTS; DIOXOLES; DRUG SYNERGISM; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; HALOPERIDOL; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA;

EID: 0344178117     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G and O'Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943-958.
2. Arai A, Kessler M, Rogers G and Lynch G (1996) Effects of a memory-enhancing drug on DL-alpha-amino-3-hyrodxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther 278:627-638.
3. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G and Lynch G (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res 638:343-346.
4. Carlsson M and Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia: Implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
5. Carpenter WT, Jr, Buchanan RW, Kirkpatrick B, Tamminga C and Wood F (1993) Strong inference, theory testing and the neuroanatomy of schizophrenia (see comments). Arch Gen Psychiatry 50:825-831.
6. Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241-253.
7. Davis CM, Moskovitz B, Nguyen MA, Tran BB, Arai A, Lynch G and Granger R (1997) A profile of the behavioral changes produced by facilitation of AMPA-type glutamate receptors. Psychopharmacology (Berl) 133:161-167.
8. Goff DC, Tsai G, Manoach DS and Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
9. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C. Horowitz A and Kelly D (1996) Double-blind placebo-controlled crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
10. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120:128-133.
11. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers G, Schehr RS and Lynch G (1997) Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146:553-559.
12. Jaber M, Cador M, Dumartin B, Normand E, Stinus L and Bloch B (1995) Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 65: 1041-1050.
13. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U and Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psvchiatry 151:1234-1236.
14. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
15. Lahti AC, Koffel B, LaPorte D and Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
16. Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers GA and Lynch G (1995) Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci 15:8023-8030.
17. Larson J, Quach CN, LeDuc BQ, Nguyen A, Rogers GA and Lynch G (1996) Effects of an AMPA receptor modulator on methamphetainine-induced hyperactivity in rats. Brain Res 738:353-356.
18. Lynch G, Ballantine P and Campbell BA (1969) Potentiation of behavioral arousal after cortical damage and subsequent recovery. Exp Neurol 23:196-206.
19. Palmer LC, Hess US, Larson J, Rogers GA, Gall CM and Lynch G (1997) Comparison of the effects of an ampakine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum. Brain Res Mol Brain Res 46:127-135.
20. Robertson GS, Vincent SR and Fibiger HC (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49:285-296.
21. Rogers GA, Thorell J.-O, Johnstrom P, Eriksson M, Ingvar M and Stone-Elander S (1997) Ampakines: Labeling with UC for PET distribution studies. J Labelled Compounds Radiapharm 40:645-647.
22. Rosse RB, Schwartz BL, Davis RE and Deutsch SI (1991) An NMDA intervention strategy in schizophrenia with "low-dose" milacemide [see comments]. Clin Neuropharmacol 14:268-272.
23. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG and Deutsch SI (1989) Glycine adjustment therapy to conventional neuroleptic treatment in schizophrenia: An open-label pilot study. Clin Neuropharmacol 12:416-424.
24. Staubli U, Perez Y, Xu FB, Rogers G, Ingvar M, Stone-Elander S and Lynch G (1994a) Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci USA 91:11158-11162.
25. Staubli U, Rogers G and Lynch G (1994b) Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91:777-781.
26. Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21-36.
27. Weinberger DR and Berman KF (1996) Prefrontal function in schizophrenia: Confounds and controversies. Philos Trans R Soc Lond B Biol Sci 351:1495-503.